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ABSTRACT 
 
As rates of obesity have increased this disease has become a common 
problem that physicians are faced with treating.  This paper aims to review the 
different options for patients and determine the best treatments for obesity.  
Modalities that are considered include dietary treatment, exercise, pharmacologic 
treatment, and weight loss surgery.  This study compares reduced calorie diets, 
low fat diets, low glycemic index/load diets, the Mediterranean diet, and low 
carbohydrate diets.  The validity of exercise as an effective prescription for 
obesity is evaluated and debunked.  Pharmacologic treatments that are 
contrasted include those drug therapies that are currently approved by the United 
States Food and Drug Administration for the long-term treatment of obesity.  
Those are orlistat, lorcaserin and phentermine/topiramate.  The surgical 
treatments reviewed include vertical banded gastroplasty, adjustable gastric 
banding, Roux-en Y gastric bypass, biliopancreatic diversion, and biliopancreatic 
diversion with duodenal switch.  After a comprehensive review of the literature 
the conclusion reached was that treatment for obesity should begin with the least 
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invasive options and those that have the least potential for harm.  That is, diet 
should be a first course of action.  Among diets a Mediterranean diet or another 
culturally adapted low glycemic index/load diet is best.  However, more studies 
are needed to determine how to translate the diets for different cultures and 
individual tastes.  When diets are unable to produce enough weight loss, 
pharmacologic treatments are considered.  Among them, lorcaserin and 
phentermine/topiramate do not have enough long-term studies to warrant a 
strong recommendation as of the publishing of this paper.  The only other option 
available, orlistat, comes with many uncomfortable gastrointestinal side effects, 
so it is also not an ideal option.  In addition, orlistat does not produce the amount 
of weight loss that is seen with surgical procedures.  Patients and physicians 
considering surgical treatment for obesity will find that the best option is 
laparoscopic adjustable gastric banding. 
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INTRODUCTION 
 
 Obesity is defined as a metabolic disorder that is diagnosed when a 
patient has body mass index (BMI) of at least 30 kg/m2 (Thompson, Cook, Clark, 
Bardia, & Levine, 2007).  A patient’s BMI describes the patient’s weight in 
relation to his or her height.  It is calculated by dividing the person’s mass in 
kilograms by height squared in meters squared (Thompson, Cook, Clark, Bardia, 
& Levine, 2007).  The idea of using BMI as a measure of healthy or unhealthy 
weight has been criticized because it does not account for differences in lean 
body mass, but that does not seem to be an issue in the obese population 
(Flegal, Carroll, Ogden, & Curtin, 2010).  
 Over one third of adults in the United States are obese.  The prevalence is 
similar between men and women, with only about one percent more women with 
obesity than men.  However, prevalence does differ between age groups and 
ethnic groups for both women and men, with the Hispanic and non-Hispanic 
black population at greater risk for obesity (Flegal, Carroll, Ogden, & Curtin, 
2010).  
 Obesity is associated with increased mortality rates and increased 
prevalence of many diseases such as type II diabetes, many cancers, and 
cardiovascular disease.  Furthermore, it is inextricably linked with metabolic 
syndrome.  Metabolic syndrome is a disorder defined by a set of comorbid 
diseases.  It is common among obese patients, and it is associated with 
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increased risk in development of cardiovascular complications and type II 
diabetes, although many patients have these prior to developing metabolic 
syndrome.  There are differing accepted definitions of metabolic syndrome.  
Generally, a patient with diagnosis of metabolic syndrome has waist-to-hip ratio 
of > 0.9 for males or > 0.85 for females and/or BMI ≥ 30, in addition to at least 
two of the following disorders: decreased high density cholesterol (< 0.9 mmol/L 
for males or < 1.0 mmol/L for females), increased triglycerides (> 1.7 mmol/L), 
hypertension (> 140/90 mmHg), and/or increased fasting plasma glucose (Eckel, 
Grundy, & Zimmet, 2005). 
 The different treatment modalities for obesity, including dietary 
intervention, increased physical activity, pharmacologic treatment, and bariatric 
surgery will be discussed.  The most respected dietary interventions include 
calorie restriction, low fat diets, low carbohydrate diets, low glycemic index/load 
diets, and the Mediterranean diet.  Exercise is also often recommended along 
with changes in diet, but as will be discussed, it is not an effective treatment for 
obesity.  Pharmacologic treatments that will be discussed include all of the 
United States Food and Drug Administration’s (FDA) currently approved 
medications for chronic weight management.  Those are orlistat (Xenical or Alli), 
Belviq (lorcaserin), and Qsymia (phentermine/topiramate).  Belviq and Qsymia 
were recently approved in the summer of 2012, and hold much promise.  Finally, 
the controversy of bariatric surgery- to cut or not to cut – will be discussed, 
including the most popular forms of bariatric surgery in the United States, vertical 
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banded gastroplasty (also known as stomach stapling or Mason Procedure), 
adjustable gastric banding (also known as Lap-Band®, when done 
laparoscopically), Roux-en-Y gastric bypass, biliopancreatic diversion, and 
biliopancreatic diversion with duodenal switch. 
 Finally, the merits of these treatments, interventions, and procedures for 
obesity will be considered.  The best choice of treatment for which patient will be 
discussed, as will ideas for future research directions. 
  
 4 
DIETARY TREATMENT 
 
Kilocalorie Restriction 
Simple kilocalorie restriction has been the cornerstone of weight loss 
recommendations since the different food groups were assigned differing 
amounts of energy levels.  Popular kilocalorie restricting diets include the highly 
commercialized Weight Watchers diet.  A very significant and controversial study 
published in 2009 in the New England Journal of Medicine comparing weight loss 
diets with differing macronutrient compositions (fat:protein:carbohydrate) found 
that there was no significant difference between groups in regards to weight loss, 
leading them to conclude that weight loss is due solely to the hypocaloric nature 
of the diet (that is, calories in less than calories out).  In the authors’ own terms, 
“reduced-calorie diets result in clinically meaningful weight loss regardless of 
which macronutrients they emphasize” (Sacks et al., 2009).  This study was 
highly publicized and sent the message that the only quality of a food that is of 
importance to a dieter should be its kilocalorie content. This notion made news 
headlines, but the study had its critics.  In an editorial piece in the same issue of 
the New England Journal of Medicine it was proposed that the data warranted 
more scrutiny (Katan, 2009).  The main criticism was that no difference was 
found between groups because of an outstanding lack of adherence to the 
prescribed diets that were supposed to differentiate them.  That is, the diets that 
subjects were actually on were essentially all the same, so one would not expect 
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to find any difference between groups.  The editorial’s author further criticized the 
lack of blinding in the study (Katan, 2009). 
 
Low Fat Diet 
The classic weight loss 
diet that has been popular in 
the United States (and 
throughout much of the western 
world) is the low fat diet.  A low 
fat diet is one that emphasizes 
decreasing dietary fat while 
increasing carbohydrates.  A 
typical low fat diet has a 
macronutrient composition in 
which 60-70% calories from 
carbohydrates, 10-20% calories from fat and 10-20% calories from protein.  See 
figure 1 for a graphic representation.  Supporters of low fat diets believe that 
kilocalories from fat are less satisfying and kilocalories from carbohydrates are 
more satisfying (Clegg & Shafat, 2010).  However, this claim has been refuted in 
many studies (Rolls et al., 1994; Sacks et al., 2009). 
Figure 1.  Pie chart indicating the 
recommended macronutrient 
composition recommended for a low fat 
diet. 
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The United States Department of Agriculture (USDA) has long 
recommended a diet low in fat and high in grains (Figure 2).  There is much 
controversy about the reasons underlying the government’s recommendations 
that include well-founded suspicions that economic interests were weighted more 
highly than questions of health when the recommendations were formed (Pollan, 
Figure 2.  USDA food pyramid used 1992-2005.  Adapted from United 
States Department of Agriculture, Center for Nutrition Policy and 
Promotion, 1996. 
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2006).  Regardless of the reasons, one thing is clear - this recommended diet 
has not deterred the American population from obesity.  
 
Glycemic Index/Load 
 The obese individual often has a disturbed blood sugar regulation 
mechanism.  Many obese individuals are pre-diabetic or already have diabetes.  
Most grain food products in the United States come in a highly processed form 
that spikes blood sugar levels, adding to the obese individual’s blood sugar 
deregulation.  Furthermore, dietary fat is known to attenuate a potential blood 
sugar spike.  For these reasons researchers drew the conclusion that diets used 
to help diabetics control their blood sugar might help obese patients lose excess 
weight.  Originally conceptualized by Dr. Jenkins and his colleagues at the 
University of Toronto as a treatment for diabetes, the Glycemic Index has proven 
to be an important tool in the battle against obesity (D. J. Jenkins et al., 1981).    
The Glycemic Index is a value assigned to a particular food that describes 
its effect on blood sugar soon after consumption.  In theory, the higher the 
Glycemic Index of a food, the higher one’s blood sugar will spike after it is eaten 
(Jenkins et al., 1981).  It is determined in the following manner.  A test subject’s 
blood glucose level is measured via blood draw or finger prick after a 12 hour 
fast.  The subject is then given a test food portion that has 50 grams of available 
carbohydrate.  Blood glucose levels are measured at 15, 30, 45, 60, 90, and 120 
minutes after the first bite of test food is consumed.  For comparison, the same 
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procedure is performed replacing the test food with either glucose or white bread.  
The curve that is drawn using the measurements is called the glycemic-response 
curve, and the area under it represents the blood sugar spike produced by the 
test food as a proportion of the test subject’s response to the glucose or white 
bread.  The percent values shown under the curve are averaged to calculate the 
glycemic index of the test food, while the glycemic index of glucose or white 
bread, depending on which one was used, is set to 100 (Wolever, Jenkins, 
Jenkins, & Josse, 1991).   
One of the criticisms of the Glycemic Index model is that some foods have 
higher carbohydrate density than others.  A response to this criticism and 
addendum to the Glycemic 
Index is the concept of 
Glycemic Load, which takes 
into account the 
carbohydrate content in a 
given serving of a particular 
food.  The macronutrient 
composition of a low 
glycemic load diet would 
consist of approximately 
40% fat, 40% low-glycemic index carbohydrate and 20% protein, as represented 
in figure 3 (McMillan-Price, Petocz, & Atkinson, 2006). 
Figure 3.  Pie chart indicating the 
recommended macronutrient composition 
recommended for a low glycemic load diet. 
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Many popular diets have presented a form of Glycemic Index and/or 
Glycemic Load in their approaches.  For example, Dr. Sears’ The Zone and Dr. 
Agatston’s The South Beach Diet were both best selling books that prescribed 
adherence to a low glycemic index/load diet (Agatston, 2003; Sears, 1995). 
 
Mediterranean Diet 
Another diet that challenged the supremacy of the low fat diet was the 
Mediterranean Diet.  This nutritional regimen was inspired by the traditional diets 
of countries along the Mediterranean coast, including Spain, Morocco, Italy, and 
Greece.  It involves consumption of large amounts of olive oil, legumes, fruits, 
vegetable, and fish (Keys, 1970).  The Mediterranean diet is relatively high in fat, 
but still provides protection from cardiac adverse events and mortality in general 
(Kris-Etherton, Eckel, Howard, St. Jeor, & Bazzarre, 2001; Menotti, Lanti, Puddu, 
& Kromhout, 2000).  An important study published in 2008 in The New England 
Journal of Medicine comparing a low carbohydrate diet, a low fat diet, and the 
Mediterranean diet in both men and women found that the three diets produced 
similar weight loss effects.  Interestingly, when the analysis was done looking 
only at the female subjects it was found that women on the Mediterranean diet 
lost an average of 3.8 kg (8.4 lbs.) more weight than on the low carbohydrate diet 
(Shai et al., 2008).  Most recently, in 2011 a meta-analysis of 50 studies was 
conducted that looked at how the Mediterranean diet effects metabolic 
syndrome.  The meta-analysis found that adherence to the Mediterranean diet 
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correlated with lowered blood pressure, reduced fasting plasma glucose, and 
decreased triglycerides (Kastorini et al., 2011). 
 
Low Carbohydrate Diet 
Given that carbohydrates are the source of a food’s sugar and thus the 
source of blood sugar spikes, scientists and health care providers have 
postulated that the simple recommendation of decreasing carbohydrate 
consumption might be the best dietary approach to treat obesity and its 
comorbidities.   
 A low carbohydrate diet 
is a pattern of nutrition in 
which calories come mostly 
from protein and fat, instead 
of carbohydrates.  A typical 
low carbohydrate diet has a 
macronutrient composition in 
which 10-20% calories from 
carbohydrates, 50-60% 
calories from fat and 20-30% 
calories from protein.  See 
figure 4 for a graphic representation of this macronutrient composition.   
Figure 4.  Pie chart indicating the 
recommended macronutrient composition 
recommended for a low carbohydrate diet. 
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The quintessential low carbohydrate diet is the Atkins Diet, which was 
popularized by cardiologist Dr. Robert C. Atkins in his books published in 1973, 
1992, and 2002 (Foster et al., 2003).  Atkins Nutritionals has created its own food 
pyramid, shown in figure 5, to represent the tenants of its low carbohydrate 
Atkins Diet.   
Figure 5.  Atkins Diet food pyramid.   
Figure downloaded from Atkins Nutritionals at 
http://www.atkins.com/Science/Atkins-Food-Pyramid.aspx. 
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The base of the pyramid consists of protein rich foods that contain 
negligible amounts of carbohydrates such as eggs, tofu and animal meats.  The 
second tier from the bottom consists of non-starchy vegetables.  Next is a level 
consisting of fruits, with an emphasis on berries.  The second to last tier (from the 
bottom) consists of foods composed mostly of fats such as nuts, oils and cheese.  
The top and smallest part of the pyramid consist of whole grains.  Refined grains 
and sugars are absent from the pyramid (Atkins Nutritionals, 2012). 
According to a systematic review of the literature before 2003 the 
evidence showing the safety and efficacy of low carbohydrate diets in the 
treatment of obesity was insufficient (Bravata et al., 2003).  Then in 2003 two 
groundbreaking studies published in the same issue of The New England Journal 
of Medicine changed the scientific community’s perception of low carbohydrate 
diets like the Atkins diet.  Both studies compared obese subjects on low 
carbohydrate diets with counterparts on conventional diets defined as low in 
calories, high in carbohydrates, and low in fats.  Low carbohydrate dieters in both 
studies lost more weight than their conventional diet counterparts.  In one study 
low carbohydrate dieters lost 6.8 ± 5.0 (mean ± standard deviation) % of body 
weight while conventional dieters lost 2.7 ± 3.7 % of body weight in three months.  
After six months, weight loss was 7.0 ± 6.5 % of body weight for low 
carbohydrate dieters and 3.2 ± 5.6 % of body weight for those in the conventional 
group (Foster et al., 2003).  In the second study, after six months, weight change 
was -5.8 ± 8.6 kg in the low carbohydrate group and -1.9 ± 4.2 kg in the 
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conventional group (Samaha et al., 2003).  Furthermore, markers for 
cardiovascular health improved more in subjects on the low carbohydrate diets.  
Increases in high-density lipoprotein (HDL) and decreases in triglycerides were 
greater in the low carbohydrate groups in both studies (Foster et al., 2003; 
Samaha et al., 2003).  One of the studies additionally found a decrease in 
diastolic blood pressure and increase in insulin sensitivity in the low carbohydrate 
group (Foster et al., 2003). 
 Recently, a study published in Journal of the American Medical 
Association compared the effects of a low-fat diet, low glycemic load diet 
(moderate carbohydrate content), and a low carbohydrate diet (Ebbeling et al., 
2012).  The results indicated that although the low carbohydrate diet resulted in 
the greatest resting energy expenditure, the glycemic index diet resulted in safer 
levels of circulating stress factors, indicating that a low glycemic load diet might 
lead to better long-term outcomes (Ebbeling et al., 2012). 
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EXERCISE 
 
 Exercise alone may only facilitate fat loss in men, but not in women.  The 
fat loss in men is due to increased resting metabolic rate produced by increases 
in muscle mass from exercise.  Women lack the testosterone levels necessary 
for significant muscle mass increases from exercise, and therefore, do not benefit 
from a higher resting metabolic rate from exercise alone.  However, even in men 
the fat loss from exercise alone is rarely clinically significant.  An important, often 
cited study called “Effects of a 16-Month Randomized Controlled Exercise Trial 
on Body Weight and Composition in Young, Overweight Men and Women” 
substantiates these claims (Donnelly et al., 2003).  The study followed 17-35 
year olds with BMIs between 25.0 and 34.9 kg/m2.  Although exercise levels 
were comparable between men and women, only the exercising men lost weight, 
lowered BMI and decreased fat mass.  Men in the exercising group lost 5.2 ± 4.7 
kg in body weight, 1.6 ± 1.4 kg/m2 in BMI, and lost 4.9 ± 4.4 kg in fat mass.  
Women merely maintained all of those parameters (Donnelly et al., 2003). 
 The literature indicates that exercise’s effectiveness is maximized when it 
is paired with another weight loss technique, such as dietary changes, but even 
then the added benefit seems to be only about 1 kg with modest amounts of 
exercise added to dietary changes (Bensimhon, Kraus, & Donahue, 2006; 
Thompson, Cook, Clark, Bardia, & Levine, 2007).  Increasing the amount of time 
spent exercising to 90-120 minutes daily during combined therapy results in a 
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weight loss of 7-8 kg, versus only 3 kg with shorter duration of exercise during 
combined therapy versus only 2 kg with exercise alone (Jakicic, Marcus, 
Gallagher, Napolitano, & Lang, 2003; Thompson, Cook, Clark, Bardia, & Levine, 
2007).  
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PHARMACOLOGIC TREATMENT 
  
Pharmacologic treatment of obesity operates by interfering with absorption 
of nutrients, suppressing appetite and/or increasing metabolism.  Orlistat is an 
example of a weight loss drug that interferes with absorption of dietary fat in the 
intestine.  Drugs that suppress appetite are often catecholamines or 
catecholamine-derived compounds.  Examples include phentermine and other 
amphetamine-like stimulants, which also increase metabolism.  In addition, mood 
stabilizers and anti-depressants have been used “off label” to suppress appetite.  
Examples include bupropion and topiramate.  Lorcaserin is a newly approved 
anorectic drug that works by stimulating a specific type of serotonin receptor.  
Drugs that block cannabinoid receptors, such as Rimonabant (Acomplia), are 
another class of anti-obesity medications under investigation. 
 
Orlistat 
The most commonly used pharmacologic treatment for obesity, orlistat 
(also known as, tetrahydrolipstatin, and the trade names Xenical and Alli) is a 
compound that interferes with the absorption of nutrients.  It is produced by the 
saturation of lipstatin, a natural substance from the Streptomyces toxytricini 
bacterium (Barbier & Schneider, 1988), and interferes with the action of 
pancreatic lipases in the intestine.  The body is then unable to break down 
triglycerides into free fatty acids, and thus the ability to absorb fat molecules from 
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the diet is inhibited.  Instead, the fat is eliminated in the fecal matter.  Hence, 
patients taking orlistat experience a reduction in calories obtained from the diet 
(Mancini & Halpern, 2006). 
Orlistat comes in two formulations - prescription strength Xenical and 
over-the-counter strength Alli.  The recommended prescription strength dose is 
120 mg taken three times per day (that is, before each meal).  The 
recommended over-the-counter strength dose is 60 mg taken three times per day 
(that is, before each meal).  When patients take the prescription dose about 30% 
of the fat consumed is blocked from absorption.  At the over-the-counter dose the 
proportion of fat blocked reduces to 25%.  Orlistat’s fat absorption blocking 
effects are not dose dependent beyond the standard prescription dose (Rössner, 
Sjöström, Noack, Meinders, & Noseda, 2000). 
Orlistat has been demonstrated to be effective for weight loss.  Meta-
analysis of clinical trials for orlistat plus behavioral changes (that is, nutrition and 
physical activity) showed that by the end of one year, subjects taking orlistat lost 
2.0 - 3.0 kg, or 4.4 - 6.6 lbs., more than subjects taking a placebo (Mancini & 
Halpern, 2006).  Another meta-analysis estimated the twelve-month average 
weight loss of patients taking orlistat to be 2.89 kg (95% confidence interval: 
2.27-3.51 kg), relative to placebo (Li et al., 2005).  Figure 6 shows a summary of 
weight loss results for the studies used in that meta-analysis.  A deeper look at 
one of those clinical trials for orlistat revealed that by the end of one year 35.3% - 
54.8% of subjects decreased their body mass by greater than or equal to five 
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percent.  Furthermore, 16.4% - 24.8% of the study subjects decreased their body 
mass by greater than or equal to ten percent.  After orlistat treatment was 
discontinued subjects regained less than 35% of their original weight loss 
(Davidson et al., 1999).  
 
Figure 6.  Summary of clinical trials of orlistat used in meta-analysis: 
average difference in weight loss between patients on orlistat and those 
on placebo.  Figure taken from Li et al., 2005.  
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In addition to a promising weight loss profile, orlistat treatment has been 
demonstrated in the obese population of subjects to show improvements in blood 
pressure levels and type II diabetes prevention.  It is not clear that these 
improvements were due solely to orlistat administration, as opposed to being 
secondary to the effects of the weight loss itself, however.  After long-term use of 
orlistat the mean reduction in systolic blood pressure was 2.5 mmHg, and the 
mean reduction in diastolic blood pressure was 1.9 mmHg (Siebenhofer et al., 
2009).  One randomized controlled trial showed a 40% decrease in occurrence of 
type II diabetes among obese subjects on orlistat (Torgerson, Hauptman, Boldrin, 
& Sjostrom, 2004).  Another study showed that over four years the occurrence of 
type II diabetes among obese subjects on orlistat was 6.2%, while the incidence 
while on placebo was 9.0% (Torgerson, Hauptman, Boldrin, & Sjostrom, 2004).  
These data shed a positive light on orlistat as a viable treatment for obesity 
related disorders. 
The major downside of orlistat treatment lies in its embarrassing 
gastrointestinal side effects.  Among those side effects are flatulence, 
steatorrhea (excess fat in the feces, producing oily stools), frequent/urgent bowel 
movements, and dissolute fecal matter.  Meta-analysis of treatment effects of 
orlistat for pooled odds ratio (OR), 95% confidence interval (CI), relative risk 
(RR), and number needed to treat for harm for orlistat’s side effects are shown in 
Table 1).  For diarrhea OR was 54.85, 95% CI was 44.88 - 67.48, RR was 3.40, 
and number needed to treat for harm was 1.48.  For flatulence OR was 3.72, 
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95% CI was 3.16 – 4.39, RR was 3.10, and number needed to treat for harm was 
6.49.  For bloating, abdominal pain, and dyspepsia OR was 1.55, 95% CI was 
1.18 – 2.06, RR was 1.48, and number needed to treat for harm was 25.80.   
Other less common side effects included headache, nausea and vomiting, gall 
bladder problems, and depression and mood change.  All data were calculated 
relative to placebo (Li et al., 2005). 
 
 
 
 
 
Fortunately, many of the gastrointestinal side effects can be somewhat 
mitigated by behavior change including, for example, avoidance of high fat foods.  
One study found that flatulence and oily stools could be controlled by limiting 
dietary fat intake to a maximum of 15 grams per meal (Wyatt, Catenacci, & Hill, 
2007).  The maker of the over-the-counter version of orlistat, GlaxoSmithKline 
(London, United Kingdom), describes the gastrointestinal side effects as part of 
the “aversion therapy” that forms part of the orlistat weight loss plan.  That is, 
 
Table 1.  Adverse events reported in meta-analysis of treatment of 
obesity with orlistat.    Table taken from Li et al., 2005. 
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patients learn, via negative reinforcement, to eat a diet that is generally lower in 
fat and lower in calories (Wyatt, Catenacci, & Hill, 2007). 
Other less benign possible physical side effects from orlistat have been 
reported, including severe acute liver injury and impaired kidney function.  
Although a much more deleterious adverse effect of the medication than those 
mentioned earlier, liver injury is also much rarer.  However, given the gravity of 
severe liver injury, the United States Food and Drug Administration (FDA) 
ordered a revised safety label for orlistat on May 26, 2010 that included these 
severe side effects (U.S. Food and Drug Administration, 2010). The safety 
labeling for over the counter strength orlistat, Alli, includes a warning for kidney 
stones, while prescription strength orlistat, Xenical, indicates a risk for increased 
urinary oxalate (U.S. Food and Drug Administration, 2012c).  One large study 
showed that acute kidney injury was three times more likely in subjects using 
orlistat versus placebo (Weir et al., 2011).  Still, other studies indicate that 
although there is a correlative link, a causal link for acute kidney injury may not 
exist (Beyea, Garg, & Weir, 2012).  As with any medication, these physical side 
effects are a cause for concern, but more data and investigation is needed to 
make definitive decisions about the risks versus benefits of orlistat. 
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Lorcaserin 
Lorcaserin (also known as ADP-356 and commercially as Belviq) is a new 
anti-obesity medication.  It received FDA approval on June 27, 2012 for the 
treatment of obesity in adults with a BMI of at least 30, or adults with a BMI of at 
least 27 who additionally have one or more obesity-related comorbidities 
including hypercholesterolemia, hypertension, and/or diabetes mellitus (Smith et 
al., 2009). 
The hypothesized mechanism of action by which this drug suppresses 
appetite is by stimulating the hypothalamus’ 5-HT2C receptors.  Once these 
serotonergic receptors are stimulated, pro-opiomelanocortin is produced.  Pro-
opiomelanocortin is thought to be responsible for the eventual anorectic effects of 
lorcaserin (Smith et al., 2010). 
 Arena (San Diego, California), the pharmaceutical company responsible 
for lorcaserin, concluded the required clinical trials to achieve FDA approval on 
June 27, 2012.  Phase two and phase three clinical trials were submitted and 
considered for the drug’s eventual approval.  Until enough time has passed to 
allow for post-market research this is currently the only data available to evaluate 
this drug’s safety and efficacy (U.S. Food and Drug Administration, 2012a). 
 During the phase two clinical trials the only change that patients made in 
their lives was administration of lorcaserin (that is, subjects were not asked to 
change nutrition or increase exercise).  After twelve weeks of taking 10 mg, 15 
mg or 20 mg lorcaserin per day, subjects in the intervention group lost 4.0 
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pounds, 5.7 pounds and 7.9 pounds, respectively, on average.  The average 
weight loss of the placebo group was 0.7 pounds.  All weight was regained in all 
groups shortly after treatment cessation.  Lorcaserin was relatively well tolerated, 
so phase three clinical trials soon followed (Powell, Apovian, & Aronne, 2011). 
Three different phase three clinical trials of lorcaserin were conducted 
shortly after the positive results of the phase two trials became evident.  Each of 
the randomized placebo-controlled trials lasted at least 52 weeks and 
investigated populations of overweight and obese adults of ages 18-65 years 
with BMIs of 27 - 45 kg/m2.  In all three studies, subjects were counseled on diet 
and exercise.   
In the first of lorcaserin’s phase three clinical trials, called “Behavioral 
Modification and Lorcaserin for Overweight and Obesity Management” (BLOOM), 
subjects took either 10 mg lorcaserin twice daily or placebo two times per day.  
After one year on this regime those subjects on lorcaserin lost 5.8% body weight 
on average compared to 2.2% body weight lost on placebo.  In order to test the 
effects of lorcaserin on maintenance of weight loss after the initial 52 weeks 
researchers reassigned those patients who had lost at least five percent of their 
baseline body weight to either a new placebo group or the lorcaserin treatment 
group.  The result was that 50.3% of subjects on placebo maintained at least a 
five percent weight loss versus 67.9% of subjects on lorcaserin, a statistically 
significant difference (P<0.001).  See table 2 for a summary of the results in the 
BLOOM study (Smith et al., 2010).  
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In the second lorcaserin phase three clinical trial, called “Behavioral 
Modification and Lorcaserin Second Study for Obesity Management” 
(BLOSSOM), subjects were randomized to either placebo, 10 mg lorcaserin once 
BLOOM 
  Year 1 Year 2  
 Group % Subjects 
losing ≥ 5% 
body weight 
% Subjects 
maintaining ≥ 
5% weight 
loss 
 
 Placebo  20.3% 50.3%  
 Lorcaserin 10 
mg BID 
47.5% 67.9%  
BLOSSOM 
 Group % Subjects 
losing ≥ 5% 
body weight 
Weight 
change LSM 
95% 
confidence 
interval 
 Placebo 25% 2.8% 2.5 - 3.2% 
 Lorcaserin 10 
mg QD 
47.2% 4.7% 4.3 - 5.2% 
 Lorcaserin 10 
mg BID 
40.2% 5.8% 5.5 - 6.2% 
BLOOM-DM 
 Group % Subjects 
losing ≥ 5% 
body weight 
Weight 
change LSM 
± SEM 
 
 Placebo 16.1% -1.5 ± 0.36%  
 Lorcaserin 10 
mg QD 
44.7% -5.0 ± 0.5%  
 Lorcaserin 10 
mg BID 
37.5% -4.5 ± 0.35%  
Table 2.  Weight loss results of lorcaserin’s phase three clinical trials- 
BLOOM, BLOSSOM and BLOOM-DM as reported by Smith et al., 2010, 
Fidler et al., 2011, and O’Neil et al., 2012. 
(BID: twice daily; QD: once daily; LSM: least squares mean; SEM: 
standard error of the mean) 
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daily or 10 mg twice daily.  The least squares mean body weight losses were 
2.8% (95% CI: 2.5 - 3.2%) for placebo, 4.7% (95% CI: 4.3 - 5.2%) for lorcaserin 
once daily and 5.8% (95% CI: 5.5 - 6.2%) for lorcaserin twice daily.  Another look 
at the data shows that 25% of subjects on placebo lost at least five percent of 
body weight, while 40.2% and 47.2% lost at least five percent on either lorcaserin 
once daily or lorcaserin twice daily, respectively.  Table 2 summarizes these 
results of the BLOSSOM study (Fidler et al., 2011). 
For both the BLOSSOM and BLOOM studies, the most common side 
effects reported by subjects in the intervention groups were: headache, 
dizziness, and nausea (Fidler et al., 2011; Smith et al., 2010).  With BLOOM and 
BLOSSOM lorcaserin proved its relative safety and efficacy for treatment of 
obesity. 
 The third and final lorcaserin phase three clinical trial called “Behavioral 
Modification and Lorcaserin for Overweight and Obesity Management in 
Diabetes Mellitus” (BLOOM-DM) followed a similar protocol as the other two 
phase three clinical trials, but its subjects had to fulfill the additional inclusion 
criterion of having type II diabetes (that is, they had 7-10% glycated hemoglobin 
A1c).  Given their diabetic state, the subjects in this study also took metformin 
and/or sulfonylurea.  Over one year subjects were treated with placebo, 10 mg 
lorcaserin taken once per day or 10 mg lorcaserin taken twice per day.  The least 
squares mean ± standard error of the mean body weight changes were -1.5 ± 
0.36% for placebo, -5.0 ± 0.5% for lorcaserin once daily and -4.5 ± 0.35% for  
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lorcaserin twice daily.  The proportions of patients that lost at least five percent of  
their body weight were 16.1% on placebo, 44.7% on lorcaserin once daily and 
37.5% on lorcaserin twice daily.  Interestingly, in this study, the lower dose of 
lorcaserin (10 mg once daily) proved slightly more effective then the higher dose 
(10 mg twice daily).  See Table 2 for a summary of the results of the BLOOM-DM 
study.  Furthermore, markers for diabetes severity improved in the intervention 
groups more than in the placebo group.  HbA1c and fasting plasma glucose, both 
decreased in the intervention groups.  Frequent adverse events included 
headache, nausea, nasopharyngitis, and back pain (O'Neil et al., 2012).  
 
Phentermine/topiramate 
Drug intervention is often met with controversy especially when it 
concerns treatment of obesity, since the long-term efficacy and safety of most 
pharmacologic treatments is unclear.  For example, the one time gold standard of 
obesity drug therapy, fenfluramine/phentermine, or “fen-phen,” was eventually 
found to cause cardiac abnormalities.  Consequently, it was taken off the market 
after a number of deaths were attributed to the medication (Wadden et al., 1998).  
The phentermine half of the fen-phen duo was allowed to remain on the market. 
Phentermine, along with phendietrazine and benzphetamine, are appetite 
suppressing weight-loss drugs similar to amphetamine with its anorectic effects.  
They are approved for the short-term treatment (up to twelve weeks) of obesity in 
combination with nutritional changes and increases in exercise (Colman, 2005).  
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They are not approved for long-term treatment of obesity.  Given the lack of long-
term data as well as the lack of FDA approval for use of these drugs in the long-
term, it is not recommended that patients use them beyond the allotted twelve-
week period.   
Phentermine works in two ways- by decreasing hunger and by promoting 
the breakdown of corporal adiposity, but the main weight loss producing action is 
thought to be due to its anorectic effects.  The main adverse effects experienced 
by users are tachycardia and elevated blood pressure.  Some users may also 
experience trouble sleeping, restlessness and palpitations.  Critics of the drug 
cite that even with short-term use patients will begin to experience tolerance to 
the drug.  In addition, studies show that in the short term a weight loss of 3.5 kg 
is achievable with phentermine (Haddock, Poston, Dill, Foreyt, & Ericsson, 2002; 
Thompson, Cook, Clark, Bardia, & Levine, 2007), but most patients gain the 
weight back after discontinued use of weight-loss drugs (Li et al., 2005).  For that 
reason, many health care providers find little use these appetite suppressants 
when they are used alone (that is, not in combination with other drugs) 
(Thompson, Cook, Clark, Bardia, & Levine, 2007).    
On July 17, 2012 the FDA announced its approval of the sale and 
marketing of Qsymia (formerly known as Qnexa), a drug developed by Vivus 
Pharmaceuticals (Mountain View, California) that is a combination of 
phentermine and topiramate, for the long-term treatment of obesity (U.S. Food 
and Drug Administration, 2012b).  The topiramate (trade name Topamax) half of 
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Qsymia is an anticonvulsant used in the management of epilepsy and migraine.  
Studies show that Topamax is associated with 6% body weight loss after 24 
weeks (Li et al., 2005; Thompson, Cook, Clark, Bardia, & Levine, 2007).  
However, it is not approved as a stand-alone treatment for obesity or overweight 
(Gadde et al., 2011; Wilding, Gaal, Rissanen, Vercruysse, & Fitchet, 2004). 
 Three phase three clinical trials were considered for the recent FDA 
approval of the Qsymia.  The first of these blinded, randomized controlled trials, 
dubbed EQUIP, lasted 56 weeks.  It involved severely obese patients on either 
placebo, 3.75 mg phentermine with 23 mg topiramate controlled release 
(“3.75/23 mg”), or 15.0 mg phentermine with 92 mg topiramate controlled release 
(“15.0/92 mg”).  Subjects followed a reduced-calorie diet while taking placebo or 
either medication protocol.  The percent body weight lost was 1.6% for placebo 
and 5.1%, 10.9% respectively for the two treatment regimes.  The proportion of 
subjects losing at least 5% of their body weight was 17.3% for placebo and 
44.9%, 66.7% for the 3.75/23 mg and 15.0/92 mg treatments, respectively.  
Table 3 summarizes the results of the EQUIP study.  Common adverse events in 
this study included constipation, trouble sleeping, paraesthesia, and dry mouth 
(Allison et al., 2012).   
The second randomized control trial, called CONQUER, studied the 
effects of different doses of Qsymia on overweight and obese subjects who were 
following a reduced calorie diet.  Subjects took either placebo, 7.5 mg 
phentermine with 46 mg topiramate controlled release (“7.5/46 mg”), or 15.0 mg 
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phentermine with 92 mg topiramate controlled release (“15.0/92 mg”).  The 
change in body weight at the end of the 56-week trial was -1.4 kg for placebo, -
8.1 kg for the 7.5/46 mg treatment, and -10.2 kg for the 15.0/92 mg treatment.  
The proportion of subjects losing at least 5% of their body weight was 21% for 
placebo, 62% and 70% for the 7.5/46 mg, 15.0/92 mg treatments, respectively.  
The proportion of subjects losing at least 10% of their body weight was 7% for 
placebo and 37% and 48% for the 7.5/46 mg, 15.0/92 mg treatments, 
respectively.  See Table 3 for a summary of the weight loss results of the 
CONQUER study.  Physical adverse events were similar to those in the EQUIP 
study (Allison et al., 2012; Gadde et al., 2011). 
Psychiatric adverse events were an important concern with Qsymia 
because the topiramate half of Qsymia’s phentermine/topiramate medication duo 
has been shown to induce psychiatric problems in patients.  When used in  
monotherapy topiramate can produce depression, anxiety, irritability and 
attention disturbances (Gadde et al., 2011; Wilding, Gaal, Rissanen, Vercruysse, 
& Fitchet, 2004).  The same psychiatric adverse events occurred with statistically 
significant higher frequencies in the higher dose Qsymia group (15.0/92 mg) 
compared to placebo.  However, frequencies were small enough to bring their 
clinical significance into question.  Anxiety in the 15.0/92 mg group occurred in 
4% of subjects versus 2% on placebo.  Irritability in the 15.0/92 mg group 
occurred in 3% of subjects versus less than 1% of subjects on placebo.  Attention 
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disturbances occurred in 4% of the subjects in the 15.0/92 mg group versus less 
than 1% of those on placebo (Gadde et al., 2011). 
EQUIP (56 weeks) 
 Group Weight 
change LSM 
% Subjects 
losing ≥ 5% 
body weight 
 
 Placebo  1.6% 17.3%  
 Qsymia 
3.75/23 mg 
5.1% 44.9%  
 Qsymia 
15.0/92 mg 
10.9% 66.7%  
CONQUER (56 weeks) 
 Group Weight 
change LSM 
95% 
confidence 
interval 
% Subjects 
losing ≥ 5% 
body 
weight 
 Placebo -1.2% -1.8 - -0.7% 21% 
 Qsymia 
7.5/46 mg 
-7.8% -8.5 - -7.1% 62% 
 Qsymia 
15.0/92 mg 
-9.8% -10.4 - -9.3% 70% 
SEQUEL (additional 52 weeks) 
 Group Weight 
change* LSM 
  
 Placebo -1.8%   
 Qsymia 
7.5/46 mg 
-9.3%   
 Qsymia 
15.0/92 mg 
-10.5%   
 
Table 3.  Weight loss results of Qsymia’s phase three clinical trials- 
EQUIP, CONQUER and SEQUEL as reported by Allison 2012, Gadde 
2011 and Garvey 2012. 
* Weight change since baseline of CONQUER study 
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The third clinical trial for Qsymia, called SEQUEL, was an extension of the 
CONQUER study.  It continued where CONQUER left off and followed patients  
for another 52 weeks, so that patients were followed for a total of 108 weeks.  
Not only did subjects continue to lose more weight on Qsymia compared to 
placebo, but additionally, rates of adverse events during these last 52 weeks 
were lower than the rates of adverse events in the first 56 weeks reported in the 
CONQUER study (Garvey et al., 2012).  Table 3 summarizes the results from the 
SEQUEL study. 
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WEIGHT LOSS SURGERY 
 
The subject of surgical treatment (that is, bariatric, or gastrointestinal, 
surgery), like that of pharmacologic treatment of obesity is contentious.  Some 
physicians argue that given the possible effectiveness of other non-invasive 
treatments for obesity, when the level of patient adherence is sufficient, surgical 
treatment should not be considered as an option.  Others cite the high success 
rate of bariatric surgery and the high likelihood of patients regaining lost weight 
after undergoing non-surgical treatments (Robinson, 2009).  Most physicians 
consider bariatric surgery as a viable option only after other non-invasive 
treatments have failed their patients afflicted with morbid obesity (Bult, van 
Dalen, & Muller, 2008; Maggard et al., 2005; Robinson, 2009). 
The National Institute of Diabetes and Digestive and Kidney Diseases, National 
Institutes of Health, has issued its criteria for bariatric surgery.  They recommend 
that a candidate for weight loss surgery have a “BMI of 40 or more 
[approximately 45 kg overweight for men and 36 kg for women] or BMI between 
35 and 39.9 kg/m2 and a serious obesity-related health problem such as type II 
diabetes, heart disease, or severe sleep apnea” (National Institute of Diabetes 
and Digestive and Kidney Diseases, National Institutes of Health, 2004).  Further 
recommendations are summarized as follows.   
The patient should: 
Understand the operation and the lifestyle changes that will be 
needed;  
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Be unlikely to lose weight or maintain weight loss long term with 
nonsurgical measures; 
Be well informed about the surgical procedure and the effects of 
treatment; 
Be motivated to lose weight and improve health; 
Be aware of how life may change after the operation (e.g. the need 
to chew food well and the inability to eat large meals); 
Have no psychological contraindications to obesity surgery such as 
untreated depression or personality disorders; 
Be aware of the potential for serious complications, dietary 
restrictions, and occasional failures;  
Be committed to lifelong medical follow-up and vitamin/mineral 
supplementation;  
Realize that no method, including surgery, is guaranteed to 
produce and maintain weight loss and that success is possible only 
with long-term commitment to behavioral change and medical 
follow-up. (Thompson, Cook, Clark, Bardia, & Levine, 2007) 
 
 
The option of surgery is one that has become more attractive over the 
years since its inception for many reasons.  Most importantly, modern 
procedures such as gastric bypass, stomach stapling, Lap-Band®, and others, 
have decreased the rates of obesity-related death.  This significantly 
counterbalances the mortality rate due to bariatric surgery itself, which meta-
analysis shows is less than 1% (Maggard et al., 2005). 
Once the decision has been made to proceed with surgery, the physician 
and the patient must then decide which type of bariatric surgery is best suited for 
that patient.  Each surgery comes with its own set of risks and potential rewards 
which must all be considered carefully.  Risks to consider are mortality, 
perioperative surgical risks, post-surgery complications (both short-term and 
long-term complications), cost, and psychosocial issues.  Benefits include 
reduced overall mortality, weight loss (but rarely down to normal weight), lifestyle 
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upgrades, and improvement of most cardio-metabolic risk factors, especially 
reduced type II diabetes risk (Sjöström et al., 2004).   
Weight loss surgeries can be of three types: restrictive, malabsorptive and 
combination restrictive/malabsorptive.  Restrictive type surgeries reduce the 
volume of food that the body can physically hold, and thus patient food intake is 
reduced.  These procedures usually involve adjustments made to the stomach 
size.  Operations of this type include adjustable gastric banding (AGB) and 
vertical banded gastroplasty (VBG).  Malabsorptive procedures reduce the 
body’s ability to absorb food nutrients and thus more food energy is eliminated in 
the waste.  These usually involve a resection of the intestines.   Purely 
malabsorptive procedures are no longer performed.  Instead, physicians opt to 
perform combination restrictive/malabsorptive procedures that both limit food 
intake and food absorption.  Surgeries of this type include Roux-en Y gastric 
bypass (RGB), biliopancreatic diversion (BPD), and biliopancreatic diversion with 
duodenal switch (BPD/DS). 
 
Vertical Banded Gastroplasty 
Vertical banded gastroplasty (also known as stomach stapling or Mason 
Procedure) is a restrictive type surgical procedure that relies on staples and a 
band in the stomach to create a smaller space for food.  The staples block 
access to the fundus of the stomach.  The band makes a smaller entryway to the 
rest of the stomach (Bult, van Dalen, & Muller, 2008; National Institute of 
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Diabetes and Digestive and Kidney 
Diseases, National Institutes of 
Health, 2004).  Figure 7 shows a 
descriptive illustration of the surgery.   
A large randomized controlled 
study, called the Swedish Obese 
Subjects (SOS) Study, followed 
bariatric surgery patients for ten 
years.  It found that patients that 
underwent VBG lost 16.5% of their 
body weight at the ten year mark.  
This was more than with banding 
alone, such as is done with 
adjustable gastric banding, but less than with gastric bypass.  Figure 8 compares 
weight change for subjects in the SOS Study undergoing different surgeries 
(Sjöström et al., 2004).  
In most cases VBG is considered permanent, and it is usually performed 
as an open procedure.  Open procedures, compared to laparoscopic surgeries, 
have a greater risk for infection, more trauma to tissues, longer operation time, 
as well as longer hospital stays and recovery.  For these reasons, physicians 
prefer other weight loss surgeries that are performed laparoscopically, such as 
Figure 7.  Vertical banded 
gastroplasty.  Figure taken from 
National Institute of Diabetes and 
Digestive and Kidney Diseases, 
National Institutes of Health, 2004. 
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adjustable gastric banding (National Institute of Diabetes and Digestive and 
Kidney Diseases, National Institutes of Health, 2004). 
 
Adjustable Gastric Banding 
 Adjustable gastric banding (also known as Lap-Band®, when done 
laparoscopically) is another restrictive procedure that is commonly performed.  
The “band” refers to a hollow silicone band that is placed around the upper part 
Figure 8.  SOS study results: weight change over ten years for subjects 
with banding, vertical banded gastroplasty and gastric bypass.  Figure 
taken from Sjöström et al., 2004. 
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of the stomach in order to shrink its 
capacity to hold food.  A port near 
the surface of the skin is 
connected to the silicone band by 
a tube.  Saline can be added or 
removed via the port to the inside 
of the hollow silicone band.  
Adding saline makes the gastric 
pouch that receives food smaller, 
and removing saline expands the 
gastric pouch volume.  Thus, the 
procedure is adjustable after 
surgery.  See figure 9 for an 
illustration of adjustable gastric 
banding (Bult, van Dalen, & Muller, 2008; National Institute of Diabetes and 
Digestive and Kidney Diseases, National Institutes of Health, 2004). 
 The surgical risks with laparoscopically performed adjustable gastric 
banding are minor, and some consider it to be “the safest bariatric procedure” 
(Hainer, Toplak, & Mitrakou, 2008).  The rate of mortality for this type of 
procedure is 0.05%, lower than that of any other kind of bariatric surgery (Hainer, 
Toplak, & Mitrakou, 2008).  This procedure also has the added benefit of being 
reversible (Bult, van Dalen, & Muller, 2008).  Obese patients with a BMI greater 
Figure 9.  Adjustable gastric banding.  
Figure taken from National Institute of 
Diabetes and Digestive and Kidney 
Diseases, National Institutes of 
Health, 2004. 
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than 50 kg/m2 benefit more from this type of surgery compared with their thinner 
counterparts.  Because the Lap-Band® procedure works as a weight loss aid by 
restricting food intake it cannot effectively help obese patients who already eat 
very little before the surgery.  These may be obese patients who have 
confounding medical issues or other metabolic abnormalities who despite 
continued restriction are no longer able to lose more weight for a significant 
period of time. (Hainer, Toplak, & Mitrakou, 2008).  
The SOS Study (Figure 8) reported a ten-year percent body weight loss of 
13.2% for banding surgeries like 
AGB (Sjöström et al., 2004). 
 
Roux-en-Y Gastric Bypass 
Roux-en-Y gastric bypass 
surgery works to aid in weight-loss of 
the patient by restricting the 
stomach’s capacity as well as by 
creating malabsorption of nutrients.  
In this procedure, the stomach is 
stapled to create a smaller pouch 
that is resected to the distal portion 
of the small intestine.  The proximal 
Figure 10.  Roux-en Y gastric 
bypass.  Figure taken from National 
Institute of Diabetes and Digestive 
and Kidney Diseases, National 
Institutes of Health, 2004. 
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portion of the small intestine is rejoined in such a way that a Y shape is formed 
(Bult, van Dalen, & Muller, 2008).  Figure 10 illustrates the procedure.  
One significant adverse effect observed after Roux-en-Y gastric bypass is 
reduced calcium absorption resulting in osteopenia (stemming from metabolic 
bone disease) and secondary hyperparathyroidism.  Reduced calcium absorption 
in patients that have undergone Roux-en-Y gastric bypass surgery is due to the 
fact that food is diverted from the duodenum where most calcium transporters 
are located.  
 The SOS Study (Figure 8) reported a ten-year percent body weight loss of 
25.0% for subjects that underwent RGB (Sjöström et al., 2004).  Meta-analysis 
comparing laparoscopic, open or either type of RGB found that on average 
patients that underwent laparoscopic procedures lost 38 kg, patients that 
underwent open procedures lost 43 kg and patients that underwent either type of 
RGB lost 41 kg after 36 months (Maggard et al., 2005). 
 
Biliopancreatic Diversion 
Biliopancreatic diversion (BPD) is a procedure developed to produce 
weight loss via malabsorptive mechanisms.  See figure 11 for an illustration of 
the BPD surgery.  Most patients that undergo this procedure have problems with 
malnourishment.  The problems have been severe enough to warrant a 
modification of the procedure.  Presently, biliopancreatic diversion as it was 
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classically performed is no longer in 
practice.  Instead, physicians opt to 
perform a biliopancreatic diversion 
with duodenal switch (BPD/DS).  
 According to meta-analysis 36-
month weight loss after BPD averaged 
53 kg (Maggard et al., 2005). 
 
Biliopancreatic Diversion with 
Duodenal Switch 
In BPD/DS the duodenum and 
jejunum of the small intestine are 
bypassed by connecting the end of the 
small intestine with the stomach.  See Figures 11 and 12 to compare BPD with 
BPD/DS. 
Even with the addition of the duodenal switch patients that have 
undergone the surgery can experience severe nutritional deficiencies.  For these 
patients nutritional supplements of vitamins and minerals are necessary to 
prevent complications such as anemia and osteopenia, a common complication 
of malabsorptive procedures. 
As with any procedure that results in rapid weight loss, BPD/DS patients 
are at risk for gallstones.  Thus, surgeons will either remove the gall bladder 
Figure 11.  Biliopancreatic 
diversion.  Figure taken from 
National Institute of Diabetes and 
Digestive and Kidney Diseases, 
National Institutes of Health, 
2004. 
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during surgery or they will administer 
medications to prevent gallstones after 
surgery.  In any case, patients will 
require continued monitoring for years 
after surgery.  Obese patients with a 
BMI greater than 50 kg/m2 benefit 
more from biliopancreatic diversion 
compared with their thinner 
counterparts (Hainer, Toplak, & 
Mitrakou, 2008).  
  
  
  
Figure 12.  Biliopancreatic 
diversion with duodenal switch.  
Figure taken from National 
Institute of Diabetes and Digestive 
and Kidney Diseases, National 
Institutes of Health, 2004. 
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DISCUSSION 
 
 The cause and definition of obesity is the excess fat carried by the patient.  
The goal of any treatment for obesity is to rid the patient of those unhealthy 
levels of adiposity.  The question is which method is best for whom. 
 The first modalities to consider are those that are the least invasive and 
pose the least risk that is behavior modifications in diet and exercise.  Although 
exercise should not be discouraged for its other health benefits, the evidence 
does not support its utility as a weight loss method.  For that reason it is omitted 
from this discussion.  Diet, however, is a potentially effective way to lose weight.  
The simple “calories in versus calories out” model is not effective because 
it does not account for the quality of the food consumed. Scientists in support of 
recommending a hypocaloric diet frequently cite the first law of thermodynamics 
as support for their claim that this diet is the best nutritional solution for weight 
loss (Buchholz & Schoeller, 2004).  They explain that energy “in” (in the form of 
kilocalories) must be less than energy “out.”  While that statement alone is true, 
the problem is that it neglects the thermic effect of food. The physiologic effects 
of poor quality food as well as certain hormonal responses can cause the dieter 
to over eat (Feinman & Fine, 2004). 
Low fat diets can be described as an extension of hypocaloric diets.  Fat 
has nine kilocalories per gram while the other macronutrients, carbohydrates and 
protein, each have about four kilocalories per gram.  Part of the philosophy 
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behind a low fat diet is that eating a higher fat content results in eating more 
kilocalories over all.  However, as discussed earlier this reasoning is flawed 
because it ignores the satiating effects of fat. 
Diets that focus on carbohydrates (whether quality or quantity) fare better 
than their low fat and hypocaloric counterparts.  The most robust studies show a 
greater weight loss with low carbohydrate diets.  However, given that some 
studies show elevated stress factors that could lead to heart disease are 
associated with low carbohydrate diets, this solution might not be ideal for obese 
patients who are already at a higher risk for developing cardiovascular disease, if 
they do not already have it (Ebbeling et al., 2012).When diets fail or their results 
fall short of the weight loss necessary to reduce obesity-related health risks, the 
next level of treatment options to consider should be pharmaceuticals because 
despite their side effects, the immediate risks of any surgery are greater (see 
below).  The relevant medications to consider are those approved for long term 
use, namely, orlistat (Xenical, Alli), lorcaserin (Belviq), and 
phentermine/topiramate (Qsymia).  
Bariatric surgery is the last resort option for treating obesity. Bariatric 
surgery, although very effective for weight loss, comes with many risks that 
exceed the risks that are associated with any major surgery.  It is a viable 
consideration, however, when diets and medications have failed.  Ninety percent 
of bariatric surgeries done in the United States are one of three types: 
laparoscopic Roux-en Y gastric bypass (RGB), the open approach to Roux-en Y 
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gastric bypass and laparoscopic adjustable gastric banding (AGB) (Robinson, 
2009).  Laparoscopic procedures come with fewer risks, so for most patients 
considering weight loss surgery the choice is between laparoscopic RGB and 
laparoscopic AGB.  Laparoscopic RGB produces greater weight loss but it is a 
much more complicated and riskier surgery.  It involves an irreversible resection 
of the patient’s internal organs.  Meanwhile, laparoscopic AGB produces 
significant weight loss, and it is considered a reversible procedure with less risk 
for mortality involved.  Since the major advantage of laparoscopic RGB over 
laparoscopic AGB is the potential for greater sustained weight loss with the RGB 
procedure, an important consideration is the amount of weight that the patient 
needs to lose in order to make significant improvements in health.  That 
appraised against the safety profile of the procedures are the major 
considerations. 
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CONCLUSION 
 
The problem with coming to a conclusion based on the currently available 
data is that there is a lack of robust studies showing which diet the patient will 
most likely follow successfully without quitting in a non-clinical setting.  Given that 
the Mediterranean diet is a low glycemic index diet that has been naturally 
followed for centuries by people in the Mediterranean, it seems like the likely 
winner.  However, this diet is highly culturally specific, and may not translate well 
to people of different backgrounds.  One solution might be to conduct more 
mechanistic studies of the Mediterranean Diet so that those aspects of the diet 
that produce the most health enhancing effects can be translated to different 
cultures.  For example, if studies found that it is the polyunsaturated nature of the 
fats in olive oil that are key, an effort can be made to find and promote sources of 
polyunsaturated fats from sources familiar to different cultures or encourage the 
use of olive oil instead of traditional fat sources.  Still, studies comparing the diets 
in a realistic setting must be done to uncover the most effective diet for treatment 
of obesity. 
Given that lorcaserin and phentermine/topiramate were only approved in 
2012 it would be wise to wait for post-marketing data to reveal the long-term 
safety and efficacy of the drugs.  Studies running longer than 108 weeks and 
studies replicating the results of the phase three clinical trials for these 
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medications are also warranted before the higher recommendation of these 
drugs over orlistat. 
Finally, studies that consider combined treatment regimes including diet, 
exercise, pharmaceuticals and surgery might produce better mechanisms for 
patients to lose weight. The identification of which diet works best with which type 
of surgery, and which medications are most effective in patients who have 
undergone bariatric surgery would provide useful information for treating 
physicians. The key, however, is to tailor treatments to individual patients based 
on their physiological needs as well as their ability to tolerate and maintain 
specific medications, diets and surgeries.  
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